NCT01870505View on ClinicalTrials.gov

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Metastatic or Locally-advanced Unresectable Breast Cancer

Interventions

DRUG

BYL719

DRUG

Letrozole

DRUG

Exemestane

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER